KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2023.41.36_suppl.425082
Abstract: 425082 Background: KRAS, a mediator of signalling pathways essential for cellular growth, proliferation, and survival, is the most frequently mutated oncogene in cancer. Notably, KRAS mutations occur in ~90% of pancreatic cancers, of which ~2%… read more here.
Keywords: krasg12c mutation; tumors harboring; harboring krasg12c; solid tumors ... See more keywords
First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation.
Sign Up to like & getrecommendations! Published in 2023 at "Current medicinal chemistry"
DOI: 10.2174/0929867330666230330122000
Abstract: Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRASG12C. It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRASG12C mutation in locally advanced… read more here.
Keywords: krasg12c mutation; lung cancer; non small; small cell ... See more keywords